Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Prevalent Adverse Childhood Experiences Among Young Adults Returning Home From Jail: The Need for Trauma-Informed Reentry Services

Barnert E, Applegarth DM, Bondoc C, Biely C, Leifheit KM, Grella C, Wong MD. Prevalent Adverse Childhood Experiences Among Young Adults Returning Home From Jail:[...]

CD38 regulates chronic lymphocytic leukemia proliferation via CD45 phosphatase activity

Imbery JF, Wiik C, Heinzelbecker J, Jebsen JK, Dobbing MK, Bottini N, Stanford SM, Munthe LA, Tjønnfjord GE, Tveita A, Szodoray P, Nakken B. CD38[...]

Extracellular vesicles from human breast cancer-resistant cells promote acquired drug resistance and pro-inflammatory macrophage response

Santos P, Rezende CP, Piraine R, Oliveira B, Ferreira FB, Carvalho VS, Calado RT, Pellegrini M, Almeida F. Extracellular vesicles from human breast cancer-resistant cells[...]